Publication | Open Access
From Primary MSC Culture of Adipose Tissue to Immortalized Cell Line Producing Cytokines for Potential Use in Regenerative Medicine Therapy or Immunotherapy
15
Citations
31
References
2021
Year
Cell TherapyRegenerative Medicine TherapyImmunologyCell CultureBiomedical EngineeringHatmsc1-conditioned MediumCellular PhysiologyPrimary Msc CultureRegenerative MedicineInflammationHatmsc1 Cell LineAngiogenesisStem CellsHealth SciencesAdipose TissueVascular BiologyPrimary MscsNeovascularizationCell BiologyMesenchymal Stem CellEndothelial DysfunctionStem Cell ResearchStem-cell TherapyTissue CultureMedicineExtracellular Matrix
For twenty-five years, attempts have been made to use MSCs in the treatment of various diseases due to their regenerative and immunomodulatory properties. However, the results are not satisfactory. Assuming that MSCs can be replaced in some therapies by the active factors they produce, the immortalized MSCs line was established from human adipose tissue (HATMSC1) to produce conditioned media and test its regenerative potential in vitro in terms of possible clinical application. The production of biologically active factors by primary MSCs was lower compared to the HATMSC1 cell line and several factors were produced only by the cell line. It has been shown that an HATMSC1-conditioned medium increases the proliferation of various cell types, augments the adhesion of cells and improves endothelial cell function. It was found that hypoxia during culture resulted in an augmentation in the pro-angiogenic factors production, such as VEGF, IL-8, Angiogenin and MCP-1. The immunomodulatory factors caused an increase in the production of GM-CSF, IL-5, IL-6, MCP-1, RANTES and IL-8. These data suggest that these factors, produced under different culture conditions, could be used for different medical conditions, such as in regenerative medicine, when an increased concentration of pro-angiogenic factors may be beneficial, or in inflammatory diseases with conditioned media with a high concentration of immunomodulatory factors.
| Year | Citations | |
|---|---|---|
Page 1
Page 1